This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 11
  • /
  • European Commission approves Enjaymo for treatment...
News

European Commission approves Enjaymo for treatment of hemolytic anemia in adult patients with cold agglutinin disease.- Sanofi

Read time: 1 mins
Published:20th Nov 2022

The European Commission (EC) has granted marketing authorization for Enjaymo (sutimlimab) from Sanofi, for the treatment of hemolytic anemia in adult patients with cold agglutinin disease (CAD), a rare, serious, and chronic autoimmune hemolytic anemia, where the body’s immune system mistakenly attacks healthy red blood cells and causes their rupture, known as hemolysis.

 

Enjaymo is currently the only approved treatment for CAD and is a first-in-class humanized monoclonal antibody that is designed to selectively target and inhibit the classical complement pathway specific serine protease, C1s. It will be available as a 50mg/mL solution for infusion.

Alexander Röth, MD, Department of Hematology and Stem Cell Transplantation, University Hospital, University of Duisburg-Essen, Germany, “Coupled with diagnostic journeys that can last years, the impact of fatigue on quality of life in CAD is often debilitating and is comparable to conditions such as cancer-related anemia and other autoimmune disorders. Clinicians now have a much-needed therapeutic option to offer to their patients.”

Condition: Cold Agglutinin Disease
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.